| Pathway Neurology | |
|
4907 N Florida Ave Tampa FL 33603-2119 | |
| (813) 549-1675 | |
| (813) 549-4175 |
| Full Name | Pathway Neurology |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 4907 N Florida Ave, Tampa, Florida |
| Authorized Official Name and Position | Jeffrey Arlin Rumbaugh (OWNER/PROVIDER) |
| Authorized Official Contact | 8135491475 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Pathway Neurology 4907 N Florida Ave Tampa FL 33603-2119 Ph: (813) 549-1675 | Pathway Neurology 4907 N Florida Ave Tampa FL 33603-2119 Ph: (813) 549-1675 |
| NPI Number | 1104387935 |
|---|---|
| Provider Enumeration Date | 03/26/2019 |
| Last Update Date | 08/30/2019 |
| Medicare PECOS PAC ID | 6800125550 |
|---|---|
| Medicare Enrollment ID | O20190906000204 |
News Archive
A new study suggests that psychotherapists discriminate against prospective patients who are black or working class.
Researchers at the Swedish medical university Karolinska Institutet have demonstrated that a growth hormone, PDGF-BB, and the blood protein EPO are involved in the development of cancer tumours and that they combine to help the tumours proliferate in the body.
Reduced hippocampal volumes exist in patients across the psychosis spectrum, shows the latest report from the B-SNIP study.
GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104387935 | NPI | - | NPPES |
| 1528093705 | Other | FL | INDIVIDUAL NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | (* (Not Available)) | Primary |
| Provider Name | Jeffrey Arlin Rumbaugh |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1528093705 PECOS PAC ID: 2668452053 Enrollment ID: I20150507000836 |
News Archive
A new study suggests that psychotherapists discriminate against prospective patients who are black or working class.
Researchers at the Swedish medical university Karolinska Institutet have demonstrated that a growth hormone, PDGF-BB, and the blood protein EPO are involved in the development of cancer tumours and that they combine to help the tumours proliferate in the body.
Reduced hippocampal volumes exist in patients across the psychosis spectrum, shows the latest report from the B-SNIP study.
GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).
› Verified 7 days ago
News Archive
A new study suggests that psychotherapists discriminate against prospective patients who are black or working class.
Researchers at the Swedish medical university Karolinska Institutet have demonstrated that a growth hormone, PDGF-BB, and the blood protein EPO are involved in the development of cancer tumours and that they combine to help the tumours proliferate in the body.
Reduced hippocampal volumes exist in patients across the psychosis spectrum, shows the latest report from the B-SNIP study.
GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).
› Verified 7 days ago
Avalon Behavior Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1190 E Washington St, Ph29, Tampa, FL 33602 Phone: 510-313-8290 | |
Varghese Kodiyan Pa Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 602 Shellcracker Ct, Tampa, FL 33613 Phone: 813-245-7326 | |
Tampa Life Counseling, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 13035 W. Linebaugh Ave #101 Ste G, Tampa, FL 33626 Phone: 813-906-8852 | |
Embracing Changes Center For Wellness Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 4830 W Kennedy Blvd Ste 630, Tampa, FL 33609 Phone: 813-486-4920 Fax: 813-428-5756 | |
Vip Senior Wellness Services Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 10115 Vista Pointe Dr, Tampa, FL 33635 Phone: 718-942-6595 | |
Crudup Psychological Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 10001 Cross Creek Blvd, Tampa, FL 33647 Phone: 386-243-9220 | |
Grow, Empower, Transform Therapy, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 13542 N Florida Ave Ste 210, Tampa, FL 33613 Phone: 813-563-8227 |